Study of LL-BMT1 in Patients With Elevated Intraocular Pressure
Status:
Completed
Trial end date:
2021-02-16
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 2a clinical study of LL-BMT1 in patients with primary open-angle
glaucoma and ocular hypertension. Study subjects will be treated for 7 days with a single
dose of LL-BMT1.